Haleon stock faces a tougher outlook after Q3 slowdown
Published on 11/08/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHaleon resets its growth outlook
- Haleon lowered its full-year organic revenue outlook after softer demand in respiratory health and a China regulatory disruption.
- Strong oral health performance and a further share buyback support the investment case, but execution remains the key issue.
- The next scheduled full-year results are due in February 2027.
Haleon lowered its 2026 organic revenue growth outlook on October 29 after a weaker-than-expected third quarter. In its official Q3 trading statement, the consumer health group said organic growth reached 2.6 percent in the three months ended September 30, 2026.
Growth slows outside oral health
Haleon now expects full-year organic revenue growth of around 2.5 percent, while maintaining its expectation for high-single-digit adjusted operating profit growth at constant currency. The company cited softer cough, cold and flu consumption, particularly in North America, as well as a raw material classification change affecting Centrum over-the-counter products in China.
The China issue forced Haleon to stop importing the affected Centrum products until further notice. The company said the change was not related to product quality or safety. It generated about GBP 75 million in 2025 revenue from those products.
Oral care remains the bright spot
Oral Health delivered organic growth of 8.8 percent in the quarter, making it Haleon's strongest major category. Respiratory Health declined 2.0 percent organically, while Vitamins, Minerals and Supplements fell 0.5 percent. Europe also contracted organically, whereas emerging markets grew 5.1 percent.
Haleon allocated a further GBP 500 million to share buybacks, with completion planned by the full-year results in February 2027. The capital return provides support for shareholders, but the central investment question remains whether stronger volume growth can restore confidence in the company's medium-term growth ambition.
Share price and investor calendar
Haleon stock traded at 4.08 euros on Lang & Schwarz at 13:02:51 CET on Saturday, November 7, 2026. The quote is a real-time snapshot rather than a comparison with a verified Xetra closing price. See the real-time quote of Haleon stock.
Haleon is scheduled to publish its FY 2026 results on February 25, 2027. Until then, investors are likely to focus on respiratory demand, the China product disruption and evidence that productivity gains can support margins while the company invests behind its brands.
The Haleon stock topic page provides further company coverage.
Broader market sentiment can be tracked through the FTSE 100.
Haleon plc at a glance
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Ticker: HLN
- Home exchanges: London Stock Exchange and New York Stock Exchange
- Sector: Consumer health
- Lang & Schwarz quote: 4.08 euros on November 7, 2026 at 13:02:51 CET
- Next scheduled results: FY 2026 results on February 25, 2027
